RESUMEN
Resistance to ß-lactam antibacterials, importantly via production of ß-lactamases, threatens their widespread use. Bicyclic boronates show promise as clinically useful, dual-action inhibitors of both serine- (SBL) and metallo- (MBL) ß-lactamases. In combination with cefepime, the bicyclic boronate taniborbactam is in phase 3 clinical trials for treatment of complicated urinary tract infections. We report kinetic and crystallographic studies on the inhibition of AmpC, the class C ßlactamase from Escherichia coli, by bicyclic boronates, including taniborbactam, with different C-3 side chains. The combined studies reveal that an acylamino side chain is not essential for potent AmpC inhibition by active site binding bicyclic boronates. The tricyclic form of taniborbactam was observed bound to the surface of crystalline AmpC, but not at the active site, where the bicyclic form was observed. Structural comparisons reveal insights into why active site binding of a tricyclic form has been observed with the NDM-1 MBL, but not with other studied ß-lactamases. Together with reported studies on the structural basis of inhibition of class A, B and D ßlactamases, our data support the proposal that bicyclic boronates are broad-spectrum ßlactamase inhibitors that work by mimicking a high energy 'tetrahedral' intermediate. These results suggest further SAR guided development could improve the breadth of clinically useful ß-lactamase inhibition.
Asunto(s)
Proteínas Bacterianas/antagonistas & inhibidores , Ácidos Borónicos/farmacología , Inhibidores de beta-Lactamasas/farmacología , Antibacterianos , Proteínas Bacterianas/genética , Ácidos Borónicos/química , Cristalografía por Rayos X , Ciclización , Farmacorresistencia Bacteriana/efectos de los fármacos , Farmacorresistencia Bacteriana/genética , Escherichia coli/enzimología , Escherichia coli/genética , Pruebas de Sensibilidad Microbiana , beta-Lactamasas/clasificación , beta-Lactamasas/genéticaRESUMEN
The bicyclic boronate VNRX-5133 (taniborbactam) is a new type of ß-lactamase inhibitor in clinical development. We report that VNRX-5133 inhibits serine-ß-lactamases (SBLs) and some clinically important metallo-ß-lactamases (MBLs), including NDM-1 and VIM-1/2. VNRX-5133 activity against IMP-1 and tested B2/B3 MBLs was lower/not observed. Crystallography reveals how VNRX-5133 binds to the class D SBL OXA-10 and MBL NDM-1. The crystallographic results highlight the ability of bicyclic boronates to inhibit SBLs and MBLs via binding of a tetrahedral (sp3) boron species. The structures imply conserved binding of the bicyclic core with SBLs/MBLs. With NDM-1, by crystallography, we observed an unanticipated VNRX-5133 binding mode involving cyclization of its acylamino oxygen onto the boron of the bicyclic core. Different side-chain binding modes for bicyclic boronates for SBLs and MBLs imply scope for side-chain optimization. The results further support the "high-energy-intermediate" analogue approach for broad-spectrum ß-lactamase inhibitor development and highlight the ability of boron inhibitors to interchange between different hybridization states/binding modes.
Asunto(s)
Ácidos Borínicos/farmacología , Boro/farmacología , Compuestos Bicíclicos con Puentes/farmacología , Ácidos Carboxílicos/farmacología , Inhibidores de beta-Lactamasas/farmacología , beta-Lactamasas/química , Antiinfecciosos/farmacología , Dominio Catalítico , Cristalografía por Rayos X , Diseño de Fármacos , Escherichia coli/efectos de los fármacos , Humanos , Concentración 50 Inhibidora , Klebsiella pneumoniae/efectos de los fármacos , Espectroscopía de Resonancia Magnética , Pruebas de Sensibilidad Microbiana , Oxígeno/química , SolventesRESUMEN
Routes to bicyclic tetramates derived from cysteine permitting ready incorporation of functionality at two different points around the periphery of a heterocyclic skeleton are reported. This has enabled the identification of systems active against Gram-positive bacteria, some of which show gyrase and RNA polymerase inhibitory activity. In particular, tetramates substituted with glycosyl side chains, chosen to impart polarity and aqueous solubility, show high antibacterial activity coupled with modest gyrase/polymerase activity in two cases. An analysis of physicochemical properties indicates that the antibacterially active tetramates generally occupy physicochemical space with MW of 300-600, clog D7.4 of -2.5 to 4 and rel. PSA of 11-22%. This work demonstrates that biologically active 3D libraries are readily available by manipulation of a tetramate skeleton.
Asunto(s)
Antibacterianos/farmacología , Compuestos Bicíclicos con Puentes/farmacología , Cisteína/farmacología , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Antibacterianos/síntesis química , Antibacterianos/química , Compuestos Bicíclicos con Puentes/síntesis química , Compuestos Bicíclicos con Puentes/química , Cisteína/química , Pruebas de Sensibilidad Microbiana , Estructura MolecularRESUMEN
The ß-lactams remain the most important antibacterials, but their use is increasingly compromised by resistance, importantly by ß-lactamases. Although ß-lactam and non-ß-lactam inhibitors forming stable acyl-enzyme complexes with nucleophilic serine ß-lactamases (SBLs) are widely used, these are increasingly susceptible to evolved SBLs and do not inhibit metallo-ß-lactamases (MBLs). Boronic acids and boronate esters, especially cyclic ones, can potently inhibit both SBLs and MBLs. Vaborbactam, a monocyclic boronate, is approved for clinical use, but its ß-lactamase coverage is limited. Bicyclic boronates rapidly react with SBLs and MBLs forming stable enzyme-inhibitor complexes that mimic the common anionic high-energy tetrahedral intermediates in SBL/MBL catalysis, as revealed by crystallography. The ability of boronic acids to 'morph' between sp2 and sp3 hybridisation states may help enable potent inhibition. There is limited structure-activity relationship information on the (bi)cyclic boronate inhibitors compared to ß-lactams, hence scope for creativity towards new boron-based ß-lactamase inhibitors/antibacterials.
Asunto(s)
Boro/química , Inhibidores de beta-Lactamasas/farmacología , Antibacterianos/química , Antibacterianos/farmacología , Relación Estructura-Actividad , Inhibidores de beta-Lactamasas/químicaRESUMEN
Anomalous cross-peaks observed in the NOESY spectra of 2,4-disubstituted thiazolidines and oxazolidines that cannot be attributed to classical dipolar NOE or chemical exchange peaks have been investigated experimentally and computationally and have been shown to arise from scalar cross-relaxation of the first kind. This process is stimulated by the relatively slow modulation of scalar couplings and, for the systems studied, arises from slow on-off proton exchange of the amino nitrogen, a process influenced by solution temperature, acidity, and concentration. The mechanism is likely to be significant for many systems in which proton exchange occurs on the millisecond time scale, and misinterpretation of these cross-peaks may lead to erroneous conclusions should their true origins not be recognized.
RESUMEN
Chemoselective Dieckmann cyclisation reactions on N-malonyl thiazolidine templates derived from cysteine and pivaldehyde or aromatic aldehydes may be used to access bicyclic tetramates, for which different pathways operate as a result of differing ring-chain tautomeric behaviour of the respective intermediate imines.